Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.

Cancer chemotherapy and pharmacology ·Vol. 7 ·No. 2-3 ·1982-00-00 ·Pages 231-3

Perez Manga G, Madrigal Alonso P, Alburquerque Carbuccia H

Abstract

暂无摘要

MeSH Terms

Adult Antineoplastic Combined Chemotherapy Protocols Breast Neoplasms/drug therapy Cyclophosphamide/therapeutic use Doxorubicin/adverse effects,therapeutic use Drug Resistance Drug Therapy, Combination Etoposide/adverse effects,therapeutic use Female Fluorouracil/therapeutic use Humans Methotrexate/therapeutic use Middle Aged Neoplasm Metastasis Podophyllotoxin/analogs & derivatives

Chemicals

Etoposide Doxorubicin Cyclophosphamide Podophyllotoxin Fluorouracil Methotrexate

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Perez Manga G

Madrigal Alonso P

Alburquerque Carbuccia H

Supplementary Concepts

CMF regimen (Protocol)

References (4)

4 references, click to expand

Combination chemotherapy with adriamycin and cyclophosphamide for advanced breast cancer.
Cancer. 1975 Jul;36(1):90-7 PMID: 1203853
Etoposide (VP-16-213).
Cancer Treat Rev. 1979 Jun;6(2):107-24 PMID: 385138
Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer.
Cancer Chemother Rep. 1974 Nov-Dec;58(6):877-82 PMID: 4614896
An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer.
Oncology. 1980;37(3):149-51 PMID: 7360486

Article Info

Journal

Cancer chemotherapy and pharmacology

Abbr.

Cancer Chemother Pharmacol

ISSN

0344-5704

DOI

10.1007/BF00254557

Published

1982-00-00

Pages

231-3

Language

English

Region

Germany

NLM ID

7806519

Subset

External Links

PubMed source DOI: 10.1007/BF00254557 View journal details

Analysis Services

Adriamycin and VP16-213 combination treatment for breast cancer previously treated by the CMF regimen.

Contact

WeChat Official Account